Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.

Autor:	Lapointe HR; British Columbia Centre for Excellence in HIV/AIDS, Vancouver., Mwimanzi F; Faculty of Health Sciences., Cheung PK; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Faculty of Health Sciences., Sang Y; Faculty of Health Sciences., Yaseen F; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby., Speckmaier S; British Columbia Centre for Excellence in HIV/AIDS, Vancouver., Barad E; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Faculty of Health Sciences., Moran-Garcia N; British Columbia Centre for Excellence in HIV/AIDS, Vancouver., Datwani S; Faculty of Health Sciences., Duncan MC; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Faculty of Health Sciences., Kalikawe R; Faculty of Health Sciences., Ennis S; Faculty of Health Sciences., Young L; Division of Medical Microbiology and Virology., Ganase B; AIDS Research Program, St. Paul's Hospital., Omondi FH; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Faculty of Health Sciences., Umviligihozo G; Faculty of Health Sciences., Dong W; British Columbia Centre for Excellence in HIV/AIDS, Vancouver., Toy J; British Columbia Centre for Excellence in HIV/AIDS, Vancouver., Sereda P; British Columbia Centre for Excellence in HIV/AIDS, Vancouver., Burns L; Department of Pathology and Laboratory Medicine, Providence Healthcare, Vancouver., Costiniuk CT; Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre and Research Institute of the McGill University Health Centre, Montreal, Quebec., Cooper C; Department of Medicine, University of Ottawa.; Ottawa Hospital Research Institute, Ottawa., Anis AH; School of Population and Public Health.; CIHR Canadian HIV Trials Network, University of British Columbia.; Centre for Health Evaluation and Outcome Sciences, Vancouver., Leung V; Division of Medical Microbiology and Virology.; Department of Pathology and Laboratory Medicine, Providence Healthcare, Vancouver.; Department of Pathology and Laboratory Medicine, University of British Columbia., Holmes D; Department of Pathology and Laboratory Medicine, Providence Healthcare, Vancouver.; Department of Pathology and Laboratory Medicine, University of British Columbia., DeMarco ML; Department of Pathology and Laboratory Medicine, Providence Healthcare, Vancouver.; Department of Pathology and Laboratory Medicine, University of British Columbia., Simons J; Department of Pathology and Laboratory Medicine, Providence Healthcare, Vancouver.; Department of Pathology and Laboratory Medicine, University of British Columbia., Hedgcock M; Spectrum Health., Prystajecky N; Department of Pathology and Laboratory Medicine, University of British Columbia.; British Columbia Centre for Disease Control Public Health Laboratory, Vancouver., Lowe CF; Division of Medical Microbiology and Virology.; Department of Pathology and Laboratory Medicine, Providence Healthcare, Vancouver.; Department of Pathology and Laboratory Medicine, University of British Columbia., Romney MG; Division of Medical Microbiology and Virology.; Department of Pathology and Laboratory Medicine, Providence Healthcare, Vancouver.; Department of Pathology and Laboratory Medicine, University of British Columbia., Barrios R; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; School of Population and Public Health., Guillemi S; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Department of Family Practice, Faculty of Medicine, University of British Columbia., Brumme CJ; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Department of Medicine, University of British Columbia, Vancouver, Canada., Montaner JSG; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Department of Medicine, University of British Columbia, Vancouver, Canada., Hull M; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Department of Medicine, University of British Columbia, Vancouver, Canada., Harris M; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Department of Family Practice, Faculty of Medicine, University of British Columbia., Niikura M; Faculty of Health Sciences., Brockman MA; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Faculty of Health Sciences.; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby., Brumme ZL; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Faculty of Health Sciences.
Jazyk:	angličtina
Zdroj:	AIDS (London, England) [AIDS] 2023 Apr 01; Vol. 37 (5), pp. 709-721. Date of Electronic Publication: 2022 Dec 22.
DOI:	10.1097/QAD.0000000000003469
Abstrakt:	Background: Limited data exist regarding longer term antibody responses following three-dose coronavirus disease 2019 (COVID-19) vaccination, and the impact of a first SARS-CoV-2 infection during this time, in people with HIV (PWH) receiving suppressive antiretroviral therapy (ART). We quantified wild-type-specific, Omicron BA.1-specific and Omicron BA.5-specific responses up to 6 months post-third dose in 64 PWH and 117 controls who remained COVID-19-naive or experienced their first SARS-CoV-2 infection during this time. Design: Longitudinal observational cohort. Methods: We quantified wild-type-specific and Omicron-specific anti-Spike receptor-binding domain IgG concentrations, ACE2 displacement activities and live virus neutralization at 1, 3 and 6 months post-third vaccine dose. Results: Third doses boosted all antibody measures above two-dose levels, but BA.1-specific responses remained significantly lower than wild-type-specific ones, with BA.5-specific responses lower still. Serum IgG concentrations declined at similar rates in COVID-19-naive PWH and controls post-third dose (median wild-type-specific and BA.1-specific half-lives were between 66 and 74 days for both groups). Antibody function also declined significantly yet comparably between groups: 6 months post-third dose, BA.1-specific neutralization was undetectable in more than 80% of COVID-19 naive PWH and more than 90% of controls. Breakthrough SARS-CoV-2 infection boosted antibody concentrations and function significantly above vaccine-induced levels in both PWH and controls, though BA.5-specific neutralization remained significantly poorer than BA.1 even post-breakthrough. Conclusion: Following three-dose COVID-19 vaccination, antibody response durability in PWH receiving ART is comparable with controls. PWH also mounted strong responses to breakthrough infection. Due to temporal response declines, however, COVID-19-naive individuals, regardless of HIV status, would benefit from a fourth dose within 6 months of their third. (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu